Sun Pharma Share Price in Focus; ARC Partner Receives USFDA Complete Response Letter for PDP-716 Drug Application

Sun Pharma Advanced Research Company (SPARC) has informed exchanges that its licensing partner, Ocuvex Therapeutics Inc., has received a Complete Response Letter (CRL) from the US Food and Drug Administration (USFDA) regarding the New Drug Application (NDA) for PDP-716. 

The regulatory communication was linked to inspection-related observations at the finished product manufacturing facility, while no additional concerns were raised about the application itself.

USFDA Issues Complete Response Letter

In a regulatory filing submitted under SEBI’s Listing Obligations and Disclosure Requirements regulations, SPARC stated that Ocuvex Therapeutics received the CRL from the USFDA for PDP-716.

The company clarified that the regulator’s response was associated with findings identified during an inspection of the manufacturing site responsible for the finished product.

Manufacturing Facility Observations Cited

According to the filing, the USFDA did not raise any concerns related to the clinical or scientific aspects of the drug application. The observations were limited to the manufacturing facility involved in the production process.

A Complete Response Letter is generally issued when the USFDA concludes that a drug application cannot be approved in its current form and requires further corrective measures, clarifications or additional information before proceeding.

PDP-716 NDA Under Regulatory Review

PDP-716 is a drug candidate for which Ocuvex Therapeutics had submitted a New Drug Application to the USFDA for regulatory review. Ocuvex acts as the licensing partner for the product.

While the company did not specify a revised timeline for the approval process, such regulatory responses typically require applicants to address the identified issues before resubmission.

Market Reaction Following the Update

The regulatory development weighed on investor sentiment, with SPARC shares witnessing pressure after the announcement. Regulatory setbacks involving product approvals can impact timelines related to commercialisation and future revenue expectations.

Investors generally monitor updates related to manufacturing compliance and regulatory clearances closely, particularly in the pharmaceutical sector.

Sun Pharmaceutical Industries Share Price Performance

Shares of Sun Pharmaceutical Industries were trading at ₹1,887.10 on May 20, 2026, at 10:59 AM, compared to the previous close of ₹1,882.30. The stock gained ₹4.80, reflecting an increase of 0.26% during the session.

Read More: Alembic Pharma Share in Focus After USFDA Tentative Approval for Generic Prostate Cancer Drug.

Want to read stock market updates in Hindi? Angel One News gives comprehensive share market news in Hindi.

Conclusion

The USFDA’s Complete Response Letter for PDP-716 marks a regulatory hurdle for Ocuvex Therapeutics and Sun Pharma Advanced Research Company. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks. Read all related documents carefully before investing.